FDA Says J&J Vaccine Meets Requirements For Emergency Use Authorization
Updated: Feb 25
On Wednesday, the FDA announced that the Johnson & Johnson Covid-19 vaccine has met the requirements necessary for emergency use authorization. If approved, it would be the first single-dose vaccine authorized to treat the virus.
The Johnson & Johnson vaccine was found to be 66.9% effective at preventing moderate to severe Covid-19 symptoms and 85% effective against very serious symptoms. The J&J vaccine was less effective against the mutated South African version of the virus.
The FDA analysis says "there were no specific safety concerns identified in subgroup analyses by age, race, ethnicity, medical comorbidities, or prior SARS-CoV-2 infection" with the J&J vaccine.
The FDA committee will meet on Friday to make the final determination if the J&J vaccine receives emergency use approval.
J&J says they can roll-out 100 million doses by the end of June, if they receive FDA approval.
Although less effective than the two-dose Pfizer and Moderna vaccines, J&J's single-dose vaccine could be much easier to roll-out and does not require the same sub-zero refrigeration, facilitating transportation and storage.
Photo Source: Pixabay